R&D
Good cholesterol may not lower heart risk, study suggests
May 17, 2012
Bloomberg NewsRaising good cholesterol, a goal pursued by Eli Lilly and Co. as the next milestone in cardiac care, may not cut heart-attack
risk, says a study that challenges the development of drugs that may someday generate billions of dollars in sales.
MoreRoche scraps hoped-for cholesterol blockbuster
May 7, 2012
Associated PressA second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor
has failed in testing, casting doubt on whether any of the drugs will ever make it to pharmacies. Eli Lilly is developing
a similar drug.
MoreLilly letting U.S. researchers test failed compounds for new uses
May 3, 2012
Bloomberg NewsMore than 20 compounds that Eli Lilly and Co., Pfizer Inc. and AstraZeneca Plc failed to turn into drugs will be tested by
U.S.-sponsored scientists in a $20 million program to see if they’ll work against ailments they weren’t aimed
at previously.
MoreEndocyte could get $1B from Merck development deal
April 16, 2012
Associated PressEndocyte Inc. stock more than doubled in premarket trading after the company entered into an agreement to develop its ovarian
cancer treatment with pharmaceutical giant Merck & Co.
MoreEndocyte pulls trigger on European drug submission
March 13, 2012
J.K. WallEndocyte Inc. will submit its ovarian cancer drug EC145 for European market approval in the third quarter of this year after
the European Commission granted it orphan drug status.
MoreFDA removes hurdle in Endocyte's path to drug approval
March 5, 2012
J.K. WallEndocyte Inc. can start enrolling patients again in a clinical trial of its experimental cancer drug, the company announced
Monday, clearing away a hurdle to getting the drug approved in Europe.
MoreLechleiter bets history will repeat for Lilly
January 16, 2012
J.K. WallEli Lilly and Co. CEO John Lechleiter keeps pouring more money into research and development, even as analysts note the payoff
of such spending has dropped off 70 percent in the last decade.
MorePressure rises as Lilly tries squeeze play
January 9, 2012
J.K. WallIndianapolis-based Eli Lilly and Co. is now in the predicament of watching revenue fall as its patents on older products expire,
even as the company needs to spend more money on marketing and research to boost sales of new drugs.
MoreLilly losing dominance in diabetes treatment
December 31, 2011
J.K. WallEli Lilly and Co., after more than a decade of setbacks, is counting on diabetes to help it survive a string of patent losses
on other products that have begun to sap the drugmaker's sales.
MoreEndocyte shares plunge on clinical trial results
December 13, 2011
J.K. WallShares of Endocyte Inc. plummeted more than 60 percent Tuesday morning after clinical trial results showed the company’s
experimental ovarian cancer drug led to shorter survival times than treatment with a standard cancer drug.
MorePotential Lilly drug doubles good cholesterol
November 15, 2011
Bloomberg NewsEli Lilly and Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck &
Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.
MoreCash-strapped Arcadia seeks DailyMed buyer
November 15, 2011
Scott OlsonThe Indianapolis-based company is searching for a buyer for its once-promising DailyMed pharmacy service as it struggles to
pay $30 million in debt that comes due in April.
MorePotential Effient rival shows promise in study
November 14, 2011
Bloomberg NewsA study showing Johnson & Johnson and Bayer AG’s blood-thinner Xarelto succeeded where rival drugs failed could
give the companies entry to a $1 billion-plus market where Eli Lilly already competes.
MoreDrug shortages hit Lilly, Endocyte
November 7, 2011
J.K. WallThe nation’s shortage of certain drugs is threatening to affect research trials being conducted by Eli Lilly and Co.
and Endocyte Inc.
MoreQ&A
October 17, 2011
J.K. WallSherry Keramidas, who earned her doctorate in neuroscience and physiological psychology from Purdue University,
is executive director of the Maryland-based Regulatory Affairs Professionals Society, which is holding its annual conference
Oct. 22-26 at the Indiana Convention Center.
MoreLilly's Alimta get favorable opinion for new use in Europe
September 26, 2011
J.K. WallIf approved for continuation maintenance, Eli Lilly and Co.'s Alimta could be used for longer stretches in lung cancer patients,
generating more revenue.
MoreLilly: Alzheimer's patients on failed drug didn’t improve
July 19, 2011
Bloomberg NewsEli Lilly and Co. said patients with Alzheimer’s disease whose conditions worsened upon taking the experimental drug
semagacestat didn’t improve after dosing was halted.
MoreTiming good for 2-in-1 biotech drugs
July 5, 2011
J.K. WallEli Lilly and Co.’s foray into combination drugs is well-timed because the company could take advantage of some the
world’s most successful biotech medicines, which are about to see their patents expire.
MoreR&D spending soars above value of new drugs
July 5, 2011
J.K. WallTo understand the depths of the pharmaceutical industry’s recent struggles, consider this: The industry has been spending
$57 billion more per year on research and development than the value of the products it has been launching. That’s a
problem.
MoreLilly plans 10 drugs in final-stage trials by year's end
June 30, 2011
Bloomberg NewsLilly has 33 drugs in the second and third stages of clinical trials, including medicines for cancer, diabetes and Alzheimer’s
disease, up from seven in 2005, the Indianapolis-based company said Thursday.
MoreLilly plans more investment in two-in-one drugs
June 28, 2011
J.K. WallIndianapolis-based drugmaker Eli Lilly on Tuesday will announce a multimillion-dollar investment to develop drugs that act
like two medicines in one. Lilly plans to add more scientists to back the effort.
MoreLilly, partner find no Bydureon effect on heart rhythm
June 27, 2011
Bloomberg NewsEli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said an analysis of a 148-patient trial found no evidence
that their experimental Bydureon diabetes drug causes prolonged heart rhythms.
MoreLilly diabetes pill recommended for EU approval
June 24, 2011
Bloomberg NewsEli Lilly and Co. and Boehringer Ingelheim GmbH’s Trajenta medicine for Type 2 diabetes has been recommended for approval
in Europe, putting the drug on track to enter the region’s market this year.
MoreEU approves Lilly's weekly diabetes drug Bydureon
June 21, 2011
Associated PressEuropean Union regulators have approved the first once-per-week diabetes medication, the companies that developed the drug
said Tuesday.
MoreAmylin sues Lilly over drug development deal
May 16, 2011
Associated PressAmylin Pharmaceuticals Inc. said Monday it filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking
their commercialization deal for diabetes drugs by teaming with the German company Boehringer Ingelheim to develop and sell
a competing product.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
IBJ Featured Advertisers
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Maybe they should have sold the naming rights to the new airport terminal, instead of giving it away for nothing to honor some obscure politician.
Rolls Royce Terminal sounds nice, and $10 million a year licensing fee sounds pretty good right now.
The old airport terminal was a complete dump that was a patchwork of "fixes" over the decades with a confusing and frustrating maze of roads leading to it.
The new airport terminal is well worth it.
It is the first and last impression anyone coming from any real distance remembers of our community.
It is an essential service that is used everyday, unlike the $750 million football stadium.
Nothing like putting on the Ritz.
Flipsides Pretzel Crackers
The new airport was a waste of money and it was a "legacy" project for Bart Peterson. BAA, the former airport operator, did a complete study showing that if the airport spent $275 million on the old terminal, the airport would be better positioned for the future, financially. Bart Peterson and Melina Kennedy felt differently and with the help of Patrick Dooley, then airport director, they set out in spending the money to build the new terminal. No taxpayer money is used to operate the airport, but we all pay for the new and old airport facilities through higher fees.